The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...
Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven't responded to oral ...
Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...
The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.
The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...
The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used ...
The U.S. Food and Drug Administration has approved a nasal spray to treat depression—the first-ever stand-alone medication ...
People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.
The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's nasal spray, Spravato (esketamine), as the first ...
The Food and Drug Administration (FDA) approved Johnson & Johnson’s ketamine-derived nasal spray to help millions of U.S.
A ketamine-based nasal spray is officially the first and only standalone therapy available for treatment-resistant depression ...
Johnson & Johnson's Spravato nasal spray has been FDA-approved as a stand-alone therapy for adults with treatment-resistant ...